Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan;35(1):e13-e15.
doi: 10.1111/jdv.16953. Epub 2020 Oct 21.

Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men

A Goren  1 , C G Wambier  2 , S Herrera  3 , J McCoy  1 , S Vaño-Galván  4 , F Gioia  3 , B Comeche  3 , R Ron  3 , S Serrano-Villar  3 , P M Ramos  5 , F A Cadegiani  6 , M Kovacevic  7 , A Tosti  8 , J Shapiro  9 , R Sinclair  10
Affiliations

Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men

A Goren et al. J Eur Acad Dermatol Venereol. 2021 Jan.

Erratum in

  • Corrigendum.
    [No authors listed] [No authors listed] J Eur Acad Dermatol Venereol. 2021 Jul;35(7):1595. doi: 10.1111/jdv.17247. Epub 2021 Apr 24. J Eur Acad Dermatol Venereol. 2021. PMID: 34139054 Free PMC article. No abstract available.
No abstract available

PubMed Disclaimer

Conflict of interest statement

None declared.

Figures

Figure 1
Figure 1
Hospital outcomes. Prospective cohort of 77 men hospitalized due to severe COVID‐19 in Madrid, Spain. Individuals were categorized by use of anti‐androgens for at least 6 months before hospital admission, and followed for 60 days. The relative risk for intensive care unit (ICU) admission for individuals taking anti‐androgens was 0.14 (95% confidence interval: 0.02–0.94).
See this image and copyright information in PMC

References

    1. Wadman M. Sex hormones signal why virus hits men harder. Science 2020; 368: 1038–1039. - PubMed
    1. Gebhard C, Regitz‐Zagrosek V, Neuhauser HK, Morgan R, Klein SL. Impact of sex and gender on COVID‐19 outcomes in Europe. Biol Sex Differ 2020; 11: 29. - PMC - PubMed
    1. Wambier CG, Goren A, Vaño‐Galván S et al. Androgen sensitivity gateway to COVID‐19 disease severity. Drug Dev Res 2020; 81: 771–776. - PMC - PubMed
    1. Wambier CG, Vaño‐Galván S, McCoy J et al. Androgenetic alopecia present in the majority of hospitalized COVID‐19 patients – the “Gabrin sign”. J Am Acad Dermatol 2020; 83: 680–682. - PMC - PubMed
    1. Montopoli M, Zumerle S, Vettor R et al. Androgen‐deprivation therapies for prostate cancer and risk of infection by SARS‐CoV‐2: a population‐based study (N = 4532). Ann Oncol 2020; 31: 1040–1045. - PMC - PubMed